Collectively, the pharmaceutical blockade of NOS1 through its specific inhibitor Nω-Propyl-L-arginine is a promising therapeutic strategy for hypercholesterolemia-related CRC. This evidence concerns the gene NOS1 and colorectal carcinoma.